Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study

NCT07464366 is registered in ClinicalTrials.gov with Ji Dongmei as lead sponsor.

NCT NCT07464366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07464366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study
Lead sponsor
Ji Dongmei
Phase
Phase 2
Overall status
Recruiting
Start date
March 19, 2026
Completion date
September 30, 2029
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

salivary gland carcinomas